These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

64 related items for PubMed ID: 17453593

  • 1. Differential improvement in survival among patients with AIDS after the introduction of HAART.
    Couzigou C, Semaille C, Le Strat Y, Pinget R, Pillonel J, Lot F, Cazein F, Vittecoq D, Desenclos JC, Aids Survival Study Group.
    AIDS Care; 2007 Apr; 19(4):523-31. PubMed ID: 17453593
    [Abstract] [Full Text] [Related]

  • 2. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
    Pezzotti P, Dorrucci M, Donisi A, Cusini M, Mazzarello G, De Luca A, Salassa B, Ursitti MA, Giuliani M, Rezza G, l'Italian Seroconversion Study.
    Epidemiol Prev; 2003 Apr; 27(6):348-55. PubMed ID: 15058363
    [Abstract] [Full Text] [Related]

  • 3. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B, MANIF 2000 Study Group.
    Antivir Ther; 2005 Apr; 10(1):53-61. PubMed ID: 15751763
    [Abstract] [Full Text] [Related]

  • 4. Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters.
    Cain LE, Cole SR, Chmiel JS, Margolick JB, Rinaldo CR, Detels R.
    Am J Epidemiol; 2006 Feb 15; 163(4):310-5. PubMed ID: 16371516
    [Abstract] [Full Text] [Related]

  • 5. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH, Chan KC, Lee SS.
    Clin Infect Dis; 2004 Sep 15; 39(6):853-60. PubMed ID: 15472819
    [Abstract] [Full Text] [Related]

  • 6. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, Mercié P, Beylot J, Dabis F, Salamon R, Morlat P, Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA).
    HIV Med; 2005 May 15; 6(3):198-205. PubMed ID: 15876287
    [Abstract] [Full Text] [Related]

  • 7. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, Byram BR, Kheshti A, Carter JD, Graves CR, Raffanti SP, Sterling TR.
    J Infect Dis; 2007 Oct 01; 196(7):1044-52. PubMed ID: 17763327
    [Abstract] [Full Text] [Related]

  • 8. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.
    J Infect Dis; 2004 Sep 15; 190(6):1046-54. PubMed ID: 15319852
    [Abstract] [Full Text] [Related]

  • 9. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J.
    BMC Pediatr; 2007 Mar 17; 7():13. PubMed ID: 17367540
    [Abstract] [Full Text] [Related]

  • 10. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR, Pediatric AIDS Clinical Trials Group 219/219C Study Team.
    Clin Infect Dis; 2008 Feb 15; 46(4):507-15. PubMed ID: 18199042
    [Abstract] [Full Text] [Related]

  • 11. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy.
    Szczech LA, Hoover DR, Feldman JG, Cohen MH, Gange SJ, Goozé L, Rubin NR, Young MA, Cai X, Shi Q, Gao W, Anastos K.
    Clin Infect Dis; 2004 Oct 15; 39(8):1199-206. PubMed ID: 15486845
    [Abstract] [Full Text] [Related]

  • 12. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS.
    Antivir Ther; 2004 Oct 15; 9(5):713-9. PubMed ID: 15535408
    [Abstract] [Full Text] [Related]

  • 13. One year survival of HIV-infected veterans with CD4 < 100 cells/mm3: data from a veteran cohort.
    Breaux K, Gadde S, Graviss EA, Rodriguez-Barradas MC.
    AIDS Care; 2010 Jul 15; 22(7):886-94. PubMed ID: 20635253
    [Abstract] [Full Text] [Related]

  • 14. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
    Salzberger B, Hartmann P, Hanses F, Uyanik B, Cornely OA, Wöhrmann A, Fätkenheuer G.
    Infection; 2005 Oct 15; 33(5-6):345-9. PubMed ID: 16258865
    [Abstract] [Full Text] [Related]

  • 15. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT.
    AIDS; 2006 May 12; 20(8):1171-9. PubMed ID: 16691069
    [Abstract] [Full Text] [Related]

  • 16. Outpatient pharmacy care and HIV viral load response among patients on HAART.
    Castillo E, Palepu A, Beardsell A, Akagi L, Yip B, Montaner JS, Hogg RS.
    AIDS Care; 2004 May 12; 16(4):446-57. PubMed ID: 15203413
    [Abstract] [Full Text] [Related]

  • 17. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, Klein MB, Lalonde R, Piché A, Hankins CA.
    AIDS; 2004 Dec 03; 18(18):2411-8. PubMed ID: 15622317
    [Abstract] [Full Text] [Related]

  • 18. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM, Ramos Amador JT, Fernández de Miguel S, González Tomée MI, Rojo Conejo P, Ferrnado Vivas P, Clemente Vivas J, Ruiz Contreras J, Nogales Espert A.
    Pediatr Infect Dis J; 2003 Oct 03; 22(10):863-7. PubMed ID: 14551485
    [Abstract] [Full Text] [Related]

  • 19. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease.
    Hoffmann C, Chow KU, Wolf E, Faetkenheuer G, Stellbrink HJ, van Lunzen J, Jaeger H, Stoehr A, Plettenberg A, Wasmuth JC, Rockstroh J, Mosthaf F, Horst HA, Brodt HR.
    Br J Haematol; 2004 May 03; 125(4):455-62. PubMed ID: 15142115
    [Abstract] [Full Text] [Related]

  • 20. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G, Italian MASTER Cohort.
    Antivir Ther; 2007 May 03; 12(6):941-7. PubMed ID: 17926648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.